News
3 March 2023
Our portfolio of #GPCR#fluorescent ligands is growingWe have just added to our catalogue more fluorescent ligands for the C5a receptor, CELT-58 and CELT-68. The C5a anaphylatoxin chemotactic receptor 1 (C5aR, also […]
27 January 2023
WHY IS IMPORTANT TO CONSIDER MULTIPLE ASSAY TYPES FOR TARGETS CHARACTERIZATION? Usually, in the identification of new drug-like molecules for a target of interest it is […]
26 January 2023
Custom synthesis service for fluorescent ligands Celtarys provides custom chemical development services, specifically for the identification of a broad range of robust and complex fluorescent ligands […]
20 December 2022
Malignant cells often hijack the normal physiological functions of GPCRs to survive, proliferate autonomously, evade the immune system, increase their blood supply, invade their surrounding tissues […]
19 December 2022
We are glad to announce that Celtarys Research has reached a strategic research cooperation agreement with the European platform EU-OPENSCREEN (https://www.eu-openscreen.eu ), a not-for-profit European Research Infrastructure […]
18 November 2022
Our portfolio of #GPCR#fluorescent ligands is growingWe have just added to our catalogue two more fluorescent ligands for the α1-Adrenergic receptor, CELT-130 and CELT-133. α1-Adrenergic receptors play a vital role in the regulation of […]
9 November 2022
The XIV meeting of the Spanish Drug Discovery Network (SDDN) will take place in Granada, Spain, on November 24 and 25, 2022. This international conference has […]
7 November 2022
Cannabinoid receptors, CB1 and CB2 are two extensively studied targets of the GPCR family for the treatment of numerous conditions, including inflammatory diseases, autoimmune disorders, pain, […]
26 October 2022
G-protein coupled receptors (GPCRs) have been targeted mainly in a wide range of diseases. Still, few therapies have been directed against GPCRs in the field of cancer, […]